Hancock Whitney’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $373K | Sell |
1,726
-9
| -0.5% | -$1.72K | 0.01% | 630 |
|
|
2026
Q1 | $328K | Sell |
1,735
-5
| -0.3% | -$921 | 0.01% | 637 |
|
|
2025
Q4 | $306K | Hold |
1,740
| – | – | 0.01% | 664 |
|
|
2025
Q3 | $244K | Sell |
1,740
-21
| -1% | -$2.84K | ﹤0.01% | 715 |
|
|
2025
Q2 | $221K | Buy |
1,761
+81
| +5% | +$10.1K | ﹤0.01% | 719 |
|
|
2025
Q1 | $230K | Sell |
1,680
-130
| -7% | -$18.6K | 0.01% | 604 |
|
|
2024
Q4 | $277K | Sell |
1,810
-283
| -14% | -$47.7K | 0.01% | 551 |
|
|
2024
Q3 | $406K | Sell |
2,093
-15
| -0.7% | -$3.14K | 0.01% | 481 |
|
|
2024
Q2 | $489K | Sell |
2,108
-39
| -2% | -$8.48K | 0.02% | 420 |
|
|
2024
Q1 | $463K | Buy |
2,147
+120
| +6% | +$28.1K | 0.02% | 455 |
|
|
2023
Q4 | $525K | Sell |
2,027
-141
| -7% | -$34.6K | 0.02% | 429 |
|
|
2023
Q3 | $557K | Sell |
2,168
-51
| -2% | -$13.6K | 0.02% | 401 |
|
|
2023
Q2 | $632K | Sell |
2,219
-540
| -20% | -$161K | 0.02% | 394 |
|
|
2023
Q1 | $767K | Buy |
2,759
+76
| +3% | +$21K | 0.03% | 348 |
|
|
2022
Q4 | $743K | Sell |
2,683
-221
| -8% | -$62.4K | 0.03% | 354 |
|
|
2022
Q3 | $775K | Buy |
2,904
+641
| +28% | +$136K | 0.03% | 337 |
|
|
2022
Q2 | $462K | Buy |
2,263
+10
| +0.4% | +$2.04K | 0.02% | 438 |
|
|
2022
Q1 | $474K | Sell |
2,253
-286
| -11% | -$62.2K | 0.02% | 480 |
|
|
2021
Q4 | $609K | Sell |
2,539
-386
| -13% | -$99.3K | 0.02% | 445 |
|
|
2021
Q3 | $828K | Sell |
2,925
-567
| -16% | -$186K | 0.03% | 350 |
|
|
2021
Q2 | $1.21M | Sell |
3,492
-25,237
| -88% | -$7.65M | 0.04% | 372 |
|
|
2021
Q1 | $8.04M | Buy |
28,729
+3,774
| +15% | +$1.02M | 0.27% | 83 |
|
|
2020
Q4 | $6.11M | Sell |
24,955
-6,768
| -21% | -$1.75M | 0.2% | 99 |
|
|
2020
Q3 | $9M | Sell |
31,723
-1,285
| -4% | -$358K | 0.33% | 76 |
|
|
2020
Q2 | $8.83M | Buy |
33,008
+5,600
| +20% | +$1.68M | 0.34% | 68 |
|
|
2020
Q1 | $8.67M | Buy |
27,408
+11,975
| +78% | +$3.63M | 0.34% | 64 |
|
|
2019
Q4 | $4.58M | Buy |
15,433
+61
| +0.4% | +$16.9K | 0.15% | 174 |
|
|
2019
Q3 | $3.58M | Sell |
15,372
-1,264
| -8% | -$294K | 0.12% | 219 |
|
|
2019
Q2 | $3.89M | Sell |
16,636
-986
| -6% | -$228K | 0.12% | 216 |
|
|
2019
Q1 | $4.17M | Sell |
17,622
-131
| -0.7% | -$41.3K | 0.13% | 207 |
|
|
2018
Q4 | $5.34M | Sell |
17,753
-477
| -3% | -$152K | 0.18% | 170 |
|
|
2018
Q3 | $6.44M | Buy |
+18,230
| New | +$6.28M | 0.18% | 183 |
|
|
2015
Q3 | – | Sell |
-7,690
| Closed | -$3.25M | – | 523 |
|
|
2015
Q2 | $3.25M | Hold |
7,690
| – | – | 0.12% | 212 |
|
|
2015
Q1 | $3.25M | Buy |
+7,690
| New | +$3.03M | 0.12% | 212 |
|
Other funds holding BIIB
Hancock Whitney's BIIB Position: Q2 2026 in Review
Hancock Whitney reduced its Biogen (BIIB) stake by 0.52% in Q2 2026, selling an estimated $1.72K and leaving 1,726 shares worth $373K. The position accounts for 0.01% of the portfolio, ranked #630.
Hancock Whitney first reported a position in BIIB in Q1 2015 and has held it in 34 quarters since. The position peaked at $9M in Q3 2020. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Hancock Whitney held 1,726 shares of Biogen worth $373K as of Q2 2026.
- Hancock Whitney sold 9 Biogen shares in Q2 2026, an estimated $1.72K.
- Biogen made up 0.01% of Hancock Whitney's portfolio in Q2 2026, its #630 holding.
- Hancock Whitney first reported a position in Biogen in Q1 2015 and has held it in 34 quarters since.
- Hancock Whitney's Biogen position peaked at $9M in Q3 2020.
- 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Hancock Whitney's 13F filing for Q2 2026, filed 14 Aug 2026.